CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 144 enrolled
Drug / intervention
CPAP withdrawalother
Likely dose
CPAP withdrawn for 3 nightsAI-extracted
Key inclusion· 2
  • Moderate to severe obstructive sleep apnea with AHI or RDI >10
  • Currently owns a CPAP machine and able to tolerate CPAP use
Key exclusion· 8
  • Uncontrolled hypertension: systolic BP >170 or diastolic BP >110 mmHg
  • Congestive heart failure
  • Current use of clonidine or nicotinic acid
  • Insulin-dependent diabetes mellitus

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02824263
NCT02824263N/ACompleted

Metabolic Impact of Intermittent CPAP

Johns Hopkins University·interventional·Posted Jul 6, 2016·Updated Jan 2, 2024

In Brief

A clinical study evaluating CPAP withdrawal for Obstructive Sleep Apnea. Completed, enrolled 144 participants across 1 site.

Detailed Summary

Obstructive sleep apnea is a risk factor for diabetes and cardiovascular disease, by unknown mechanisms. The investigators hypothesize that sleep apnea changes glucose and lipid metabolism during sleep, which over time could lead to diabetes and cardiovascular disease. This study examines metabolic changes during sleep in patients with obstructive sleep apnea. Patients accustomed to continuous positive airway pressure (CPAP) therapy are enrolled to undergo sleep studies, either on CPAP therapy or after withdrawing from CPAP for 3 nights. During sleep, blood samples are obtained so that metabolic function can be compared between sleep apnea and CPAP nights.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 6, 2016
Enrollment StartJul 10, 2016
Primary CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 10.0 years ago

Interventions

CPAP withdrawalother

CPAP is discontinued for 3 nights.